ArticleAnnals of surgical oncology2023
The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer.
Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- Advances in the clinical applications of sodium thiosulphate.Annals of medicine · 2026Review
- Risk factors for complications after cytoreductive surgery (CRS) and HIPEC in 290 peritoneal malignancies of primary and secondary origins.Updates in surgery · 2026Article
- Protective Effect of Diuresis During Hyperthermia on Acute Kidney Injury in Cytoreductive Surgery with HIPEC.Annals of surgical oncology · 2026Article
- Prevention of Acute Kidney Injury Following CRS and HIPEC: One Strategy is Not Enough.Annals of surgical oncology · 2026Article
- The impact on sexual wellbeing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer treatment.Gynecologic oncology reports · 2026Article
- Evolving therapeutics in colorectal cancer peritoneal metastases.Cancer metastasis reviews · 2026Review
- Review
- Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer: a retrospective cohort study using inverse probability of treatment weighting.World journal of surgical oncology · 2026Article
- Prognostic Factors of Advanced Ovarian Cancer in the Era of HIPEC: A Multicenter Retrospective Study from an ESGO-Certified Center and an ESPSO-Certified Center.Biomedicines · 2026Article
- A Comprehensive Review of Margin Identification Methods in Soft Tissue Sarcoma.Current oncology (Toronto, Ont.) · 2025Review
- Small bowel obstruction and ovarian cancer: insights from a propensity-score matched study in patients with and without hyperthermic intraperitoneal chemotherapy after cytoreductive surgery.World journal of surgical oncology · 2025Article
- Immediate postoperative effects of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy using carboplatin on peritoneal tissue inflammatory and ischemic responses: an explorative porcine study.Pleura and peritoneum · 2025Article
- Dynamic Assessment of Local Abdominal Tissue Concentrations of Cisplatin During a HIPEC Procedure: Insights from a Porcine Model.Annals of surgical oncology · 2025Article
- The Prophylactic Role of Hyperthermic Intraperitoneal Chemotherapy on Spontaneously Ruptured Hepatocellular Carcinoma with Radical Resection: A Retrospective Study.Cancer management and research · 2025Article
- Review of 2022 PSOGI/RENAPE Consensus on HIPEC.Journal of surgical oncology · 2024Review
- Nephrotoxicity Associated with Cytoreductive Surgery Combined with Cisplatin-Based Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignant Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Article
- Editorial: Management of peritoneal surface malignancies. (cytoreductive surgery, HIPEC, PIPAC, and beyond).Frontiers in oncology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimWe report the results of an international consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) regimens for epithelial ovarian cancer (EOC) performed with the following goals: To define the indications for HIPEC To identify the most suitable HIPEC regimens for each indication in EOC To identify areas of future research on HIPEC To provide recommendations for some aspects of perioperative care for HIPEC
methodsThe Delphi technique was used with two rounds of voting. There were three categories of questions: evidence-based recommendations [using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system with the patient, intervention, comparator, and outcome (PICO) method], an opinion survey, and research recommendations.
resultsSeventy-three (67.5%) of 108 invited experts responded in round I, and 68 (62.9%) in round II. Consensus was achieved for 34/38 (94.7%) questions. However, a strong positive consensus that would lead to inclusion in routine care was reached for only 6/38 (15.7%) questions. HIPEC in addition to interval cytoreductive surgery (CRS) received a strong positive recommendation that merits inclusion in routine care. Single-agent cisplatin was the only drug recommended for routine care, and OVHIPEC-1 was the most preferred regimen. The panel recommended performing HIPEC for a minimum of 60 min with a recommended minimum intraabdominal temperature of 41°C. Nephroprotection with sodium thiosulfate should be used for cisplatin HIPEC.
conclusionsThe results of this consensus should guide clinical decisions on indications of HIPEC and the choice and various parameters of HIPEC regimens and could fill current knowledge gaps. These outcomes should be the basis for designing future clinical trials on HIPEC in EOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.